This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of Oral Formulation Of CUDC-101

About the Phase I Dose Escalation Trial

The Phase I clinical trial is designed as a standard dose escalation study in which a tablet form of CUDC-101 will be orally administered to patients with advanced or refractory solid tumors at two study centers in the United States. The primary objectives are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of oral CUDC-101 and to assess the bioavailability and pharmacokinetics of orally administered CUDC-101. The secondary objectives of this study are to assess safety and tolerability, to evaluate biomarkers of CUDC-101 activity and to assess preliminary anti-cancer activity.

The bioavailability of oral CUDC-101 will be assessed among patients enrolled in the first 3 dose level cohorts, who will initially receive single, matched IV and oral doses of CUDC-101 prior to initiating oral twice daily study treatment in the dose escalation portion of the study.

In the absence of dose limiting toxicity, each patient will receive oral CUDC-101 twice daily for a minimum of 21 days of continuous daily dosing (1 cycle), and may continue to receive additional cycles of study treatment until disease progression or other treatment discontinuation criteria are met.

About CUDC-101

CUDC-101 is designed as a first-in-class therapeutic to simultaneously inhibit HDAC, EGFR and Her2. To date, Curis has completed a Phase I dose escalation clinical trial of the IV formulation of CUDC-101 in 25 patients with advanced, refractory solid tumors and a Phase I expansion trial in which IV CUDC-101 was administered to 46 patients with specific tumor types, including breast, gastric, head and neck, liver and non-small cell lung cancers. The Phase I expansion trial was designed as an open-label study in which patients were treated with CUDC-101 at the MTD, which was determined in the Phase I dose escalation study to be 275 milligrams per meter squared. The primary objectives of this study were to assess the safety and tolerability of CUDC-101 when administered as a one-hour IV infusion on either a five days per week schedule (one week on/one week off) or a three days per week schedule (three weeks on/one week off).

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs